HealthLawProf Blog

Editor: Katharine Van Tassel
Concordia University School of Law

Monday, August 24, 2009

P&G May Sell Drug Business

On the brink of selling its $3 billion prescription drug business to Warner Chilcott Ltd, P&G has raised interesting considerations about the state of the pharmaceutical market. WSJ believes that factors in P&G's decision to put the business on the market include increasingly tough competition from generic brand drugs and a recent lawsuit:

One reminder of that fact: A key issue in talks to sell the unit was a lawsuit over a patent dispute between P&G and a generics unit of Boehringer Ingelheim, the WSJ says. The suit involves P&G’s ulcerative colitis drug Asacol. P&G has won similar cases in the past, the article notes, including one against Teva that involved Actonel, the osteoporosis drug that is the division’s best-selling product.

| Permalink

TrackBack URL for this entry:

Listed below are links to weblogs that reference P&G May Sell Drug Business:


Post a comment